79.54USD-2.64%Mkt Cap: 6.51B USDP/E: —Last update: 2026-06-01
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natu…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.51B USD
Enterprise Value6.13B USD
Revenue (TTM)51.48M USD
Gross Profit-283.00M USD
Net Income (TTM)-311.35M USD
Revenue/Share0.5790 USD
Last Price79.54 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees253
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.63
PEG—
EV/EBITDA-17.58
EV/Revenue119.03
P/S130.11
P/B4.19
EPS (TTM)-3.58
EPS (Forward)-4.37
52W Range
28.5069% of range103.00
52W High103.00 USD
52W Low28.50 USD
Profitability
Gross Margin0.00%
Oper. Margin-244.88%
EBITDA Margin0.00%
Profit Margin-794.04%
ROE-19.71%
ROA-17.86%
Growth
Revenue Growth55.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-232.89M USD
CapEx (TTM)1.45M USD
FCF Margin-270.54%
FCF Yield-2.14%
Net Debt-570.46M USD
Net Debt/EBITDA1.64
Balance Sheet
Debt/Equity0.05
Current Ratio10.81
Quick Ratio10.39
Book Value/Sh19.42 USD
Cash/Share7.913 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)118.27 USD
Target Range91.00 USD – 140.00 USD
# Analysts22
Ownership
Shares Out.82.26M
Float55.05M
Insiders2.08%
Institutions117.62%
Short Interest
Short Ratio20.3d
Short % Float15.70%
Short % Out.12.16%
Shares Short10.00M
Short (prev mo.)9.62M
Technical
SMA 5083.29 (-4.5%)
SMA 20070.68 (+12.5%)
Beta2.06
S&P 52W Chg27.94%
Avg Vol (30d)460.70K
Avg Vol (10d)468.95K
Technical Indicators
RSI (14)48.0
MACD-0.9932
MACD Signal-0.9389
MACD Hist.-0.0544
BB Upper87.11 USD
BB Middle82.31 USD
BB Lower77.51 USD
BB Width11.67%
ATR (14)3.163 USD
Vol Ratio (20d)0.65x